netrin-1 neutralizing antibody

Netrin-1 neutralizing antibodies are a class of therapeutic agents designed to bind and inhibit netrin-1, a secreted protein that acts as a survival factor for cancer cells by preventing apoptosis mediated by dependence receptors such as DCC (Deleted in Colorectal Cancer) and UNC5 homologues. In many aggressive cancers, netrin-1 is overexpressed to evade programmed cell death. Neutralization of netrin-1 restores these apoptotic pathways, inhibits epithelial-mesenchymal transition (EMT), and modulates the tumor microenvironment by reducing angiogenesis and suppressing myeloid-derived suppressor cell (MDSC) infiltration. The most advanced clinical candidate in this class is NP137, a humanized IgG1 monoclonal antibody developed by NETRIS Pharma. NP137 has been evaluated in Phase 1 and Phase 2 clinical trials for advanced solid tumors, including endometrial and cervical cancers, and is also being explored for the treatment of chronic bone pain associated with arthritis and cancer.

Other names

netrin-1 neutralizing antibodynetrin1 neutralizing antibodynetrin 1 neutralizing antibody